NewsEvents

Your Yourlocation: Home > Clinical observation of inhaled tiotropium bromide(136310-93-5) combined with seretide in the treatment of moderate to severe chronic obstructive pulmonary disease

To investigate the clinical value of inhaled tiotropium bromide(136310-93-5) combined with sulidazole in the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The study indicates that tiotropium bromide(136310-93-5) combined with sulindol inhalation therapy can improve the therapeutic effect, improve pulmonary function, increase the oxygen partial pressure and improve the quality of daily life of patients in stable and moderate COPD. The article published on the 23rd of 2015, "Community Medicine".

One hundred and sixteen stable and moderate COPD patients between January 2013 and January 2015 were randomly divided into control group (n = 58) and study group (n = 58). Patients in the control group were treated with seretide inhalation on the basis of routine therapy, 1 suction / time, 2 times / d. The patients in the study group were treated with tiotropium bromide(136310-93-5) inhalation on the basis of the control group (n = 1). Both groups were treated for 3 months. The clinical efficacy and pulmonary function, blood gas analysis, the British Medical Research Council dyspnea scale (MMRC), 6 minute walking test (6MWT) were observed and compared. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of the study group was 91.38%, significantly higher than the control group 70.69%, the difference was statistically significant (P <0.05). After treatment, the FVC, FEV1, FEV1% of the study group were (3.32 ± 0.41), (2.25 ± 0.32) L and (67.23 ± 8.03)%, respectively, which were significantly higher than those of the control group (2.86 ± 0.23) 0.21) L, (56.73 ± 6.42)%, the difference was statistically significant (all P <0.05). PaCO2 was (43.12 ± 2.19) mm Hg, which was significantly lower than that of the control group (65.63 ± 3.23) mm Hg, and significantly lower than that of the control group (47.23 ± 4.19) mm Hg (1 mm Hg = 0.133 k Pa) (48.62 ± 2.42) mm Hg in the control group, the difference was statistically significant (all P <0.05). The MMRC score of the study group was (1.33 ± 0.31), significantly lower than that of the control group (1.82 ± 0.41), the study group 6MWT was (432.52 ± 33.28) m, significantly longer than the control group (390.23 ± 24.38) (P <0.05).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved